Induction Chemotherapy
"Induction Chemotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.
Descriptor ID |
D060828
|
MeSH Number(s) |
E02.319.499 E02.860.500
|
Concept/Terms |
Induction Chemotherapy- Induction Chemotherapy
- Chemotherapies, Induction
- Chemotherapy, Induction
- Induction Chemotherapies
|
Below are MeSH descriptors whose meaning is more general than "Induction Chemotherapy".
Below are MeSH descriptors whose meaning is more specific than "Induction Chemotherapy".
This graph shows the total number of publications written about "Induction Chemotherapy" by people in UAMS Profiles by year, and whether "Induction Chemotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2023 | 0 | 1 | 1 | 2022 | 0 | 3 | 3 | 2021 | 0 | 3 | 3 | 2020 | 1 | 1 | 2 | 2019 | 1 | 0 | 1 | 2018 | 3 | 0 | 3 | 2017 | 1 | 3 | 4 | 2016 | 3 | 2 | 5 | 2015 | 1 | 2 | 3 | 2014 | 1 | 3 | 4 | 2013 | 1 | 3 | 4 | 2012 | 0 | 3 | 3 | 2011 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Induction Chemotherapy" by people in Profiles over the past ten years.
-
Tan CR, Derkach A, Nemirovsky D, Ciardiello A, Diamond B, Hultcrantz M, Hassoun H, Mailankody S, Shah U, Maclachlan K, Patel D, Lahoud OB, Landau HJ, Chung DJ, Shah GL, Scordo M, Giralt SA, Lesokhin A, Usmani SZ, Landgren O, Korde N. Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma. Blood Cancer J. 2023 07 25; 13(1):112.
-
Chhabra S, Callander N, Watts NL, Costa LJ, Thapa B, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Anderson LD, Bal S, Dhakal B, Nathwani N, Shah N, Medvedova E, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Schmidt T, Orlowski RZ, Shain KH, Cowan AJ, Dholaria B, Cornell RF, Jerkins JH, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG, Voorhees PM. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. Transplant Cell Ther. 2023 03; 29(3):174.e1-174.e10.
-
Nath K, Shekarkhand T, Salcedo M, Derkach A, Rueda S, Chansakul A, Hulcrantz M, Korde N, Shah UA, Tan C, Chung DJ, Lahoud OB, Hassoun H, Lesokhin AM, Landau HJ, Shah G, Scordo M, Giralt SA, Usmani SZ, Roshal M, Landgren O, Mailankody S. A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy. Leuk Lymphoma. 2022 Dec; 63(14):3488-3492.
-
Mao YY, Cai HC, Shen KN, Chang L, Zhang L, Zhang Y, Feng J, Wang W, Yang C, Zhu TN, Duan MH, Zhou DB, Cao XX, Li J. Benefit of high-dose idarubicin as induction therapy in acute myeloid leukemia: a prospective phase 2 study. Ann Hematol. 2022 Apr; 101(4):831-836.
-
Swisher EM, Aghajanian C, O'Malley DM, Fleming GF, Kaufmann SH, Levine DA, Birrer MJ, Moore KN, Spirtos NM, Shahin MS, Reid TJ, Friedlander M, Steffensen KD, Okamoto A, Sehgal V, Ansell PJ, Dinh MH, Bookman MA, Coleman RL. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 02; 164(2):245-253.
-
Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, Anderson LD, Aljurf M, Banerjee R, Bashey A, Battiwalla M, Beitinjaneh A, Chakraborty R, Chhabra S, Dhakal B, Dholaria B, Hashmi S, Janakiram M, Lee C, Lekakis L, Murthy HS, Parrondo R, Wangjam T, Usmani S, Shah N, Qazilbash M, D'Souza A. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplant Cell Ther. 2022 02; 28(2):83.e1-83.e9.
-
Foureau D, Bhutani M, Guo F, Rigby K, Leonidas M, Tjaden E, Fox A, Atrash S, Paul B, Voorhees PM, Usmani SZ. Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma. Cancer Med. 2021 10; 10(20):6933-6936.
-
Zhou X, Steinhardt MJ, Grathwohl D, Meckel K, Nickel K, Leicht HB, Krummenast F, Einsele H, Rasche L, Kort?m KM. Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma. Cancer Med. 2020 08; 9(16):5819-5826.
-
Mizrak Kaya D, Nogueras Gonz?lez GM, Harada K, Blum Murphy MA, Lee JH, Bhutani MS, Weston B, Thomas I, Rogers JE, Das P, Badgwell BD, Ajani JA. Efficacy of Three-Drug Induction Chemotherapy Followed by Preoperative Chemoradiation in Patients with Localized Gastric Adenocarcinoma. Oncology. 2020; 98(8):542-548.
-
Hsu PC, Chang JW, Wang CC, Wu CT, Lin YC, Wang CL, Lin TY, Li SH, Wu YC, Kuo SC, Yang CT, Liu CY, Chen CH. Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non-small cell lung cancer: Results of a single-arm prospective cohort study. Thorac Cancer. 2019 08; 10(8):1683-1691.
-
Afrough A, Saliba RM, Hamdi A, Honhar M, Varma A, Cornelison AM, Rondon G, Parmar S, Shah ND, Bashir Q, Hosing C, Popat U, Weber DM, Thomas S, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 11; 24(11):2197-2203.
-
Lovell DJ, Johnson AL, Huang B, Gottlieb BS, Morris PW, Kimura Y, Onel K, Li SC, Grom AA, Taylor J, Brunner HI, Huggins JL, Nocton JJ, Haines KA, Edelheit BS, Shishov M, Jung LK, Williams CB, Tesher MS, Costanzo DM, Zemel LS, Dare JA, Passo MH, Ede KC, Olson JC, Cassidy EA, Griffin TA, Wagner-Weiner L, Weiss JE, Vogler LB, Rouster-Stevens KA, Beukelman T, Cron RQ, Kietz D, Schikler K, Schmidt KM, Mehta J, Wahezi DM, Ting TV, Verbsky JW, Eberhard BA, Spalding S, Chen C, Giannini EH. Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in?Children With Polyarticular Forms of Juvenile Idiopathic?Arthritis With Clinically Inactive Disease. Arthritis Rheumatol. 2018 09; 70(9):1508-1518.
-
Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, Usmani SZ, Sieracki R, Gyawali B, Jackson JL, Asimakopoulos F, Hari PN. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Mar 01; 4(3):343-350.
-
Gore L, Triche TJ, Farrar JE, Wai D, Legendre C, Gooden GC, Liang WS, Carpten J, Lee D, Alvaro F, Macy ME, Arndt C, Barnette P, Cooper T, Martin L, Narendran A, Pollard J, Meshinchi S, Boklan J, Arceci RJ, Salhia B. A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML. Clin Epigenetics. 2017; 9:108.
-
Le T, Kinh NV, Cuc NTK, Tung NLN, Lam NT, Thuy PTT, Cuong DD, Phuc PTH, Vinh VH, Hanh DTH, Tam VV, Thanh NT, Thuy TP, Hang NT, Long HB, Nhan HT, Wertheim HFL, Merson L, Shikuma C, Day JN, Chau NVV, Farrar J, Thwaites G, Wolbers M. A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis. N Engl J Med. 2017 06 15; 376(24):2329-2340.
-
Samson CM, Mager D, Frazee S, Yu F. Remission in Pediatric Inflammatory Bowel Disease Correlates With Prescription Refill Adherence Rates. J Pediatr Gastroenterol Nutr. 2017 04; 64(4):575-579.
-
Xu XH, Zhang L, Cao XX, Li J, Zhang W, Zhu TN, Cai HC, Chen M, Han X, Yang C, Han B, Zhang Y, Zhuang JL, Zhou DB, Duan MH. Evaluation of the implementation rate of primary antifungal prophylaxis and the prognosis of invasive fungal disease in acute leukemia patients in China. J Infect Chemother. 2017 Jun; 23(6):360-367.
-
Kothari A, Shalin SC, Crescencio JC, Burgess MJ. Skin lesion in a patient with acute myeloid leukemia. Transpl Infect Dis. 2017 Feb; 19(1).
-
Kamel MK, Nasar A, Stiles BM, Altorki NK, Port JL. Video-Assisted Thoracoscopic Lobectomy Is the Preferred Approach Following Induction Chemotherapy. J Laparoendosc Adv Surg Tech A. 2017 May; 27(5):495-500.
-
Grover S, Mitra N, Wan F, Lukens JN, Sharma S, Bauman J, Masroor F, Cohen RB, Desai A, Algazy K, Alonso-Basanta M, Ahn P, Kevin Teo BK, Chalian AA, Weinstein GS, O'Malley BW, Lin A. A Single-institution Comparison of Cetuximab, Carboplatin, and Paclitaxel Induction Chemotherapy Followed by Chemoradiation (CRT) Versus CRT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN). Am J Clin Oncol. 2016 10; 39(5):522-7.
-
Kamel MK, Rahouma M, Ghaly G, Nasar A, Port JL, Stiles BM, Nguyen AB, Altorki NK, Lee PC. Clinical Predictors of Persistent Mediastinal Nodal Disease After Induction Therapy for Stage IIIA N2 Non-Small Cell Lung Cancer. Ann Thorac Surg. 2017 Jan; 103(1):281-286.
-
Subari S, Baidoun F, Hreh M, Patnaik M, Hashmi S, Elliott M, Hogan W, Litzow M, Al-Kali A. Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy. Int J Hematol. 2016 Apr; 103(4):409-15.
-
de Tute RM, Rawstron AC, Gregory WM, Child JA, Davies FE, Bell SE, Cook G, Szubert AJ, Drayson MT, Jackson GH, Morgan GJ, Owen RG. Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen. Haematologica. 2016 Feb; 101(2):e69-71.
-
Usmani SZ, Sexton R, Ailawadhi S, Shah JJ, Valent J, Rosenzweig M, Lipe B, Zonder JA, Fredette S, Durie B, Hoering A, Bartlett B, Orlowski RZ. Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211. Blood Cancer J. 2015 Aug 07; 5:e334.
-
Viazis N, Koukouratos T, Anastasiou J, Giakoumis M, Triantos C, Tsolias C, Theocharis G, Karamanolis DG. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation. Eur J Gastroenterol Hepatol. 2015 Apr; 27(4):436-41.
-
Brioli A, Perrone G, Patriarca F, Pezzi A, Nobile F, Ballerini F, Motta MR, Ronconi S, Tacchetti P, Catalano L, Zannetti BA, Rizzi S, Volpe S, Zamagni E, Liberati AM, Mancuso K, Boccadoro M, Davies FE, Morgan GJ, Palumbo A, Cavo M. Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. Bone Marrow Transplant. 2015 May; 50(5):673-8.
-
Coleman EA, Lee JY, Erickson SW, Goodwin JA, Sanathkumar N, Raj VR, Zhou D, McKelvey KD, Apewokin S, Stephens O, Enderlin CA, Vangsted AJ, Reed PJ, Anaissie EJ. GWAS of 972 autologous stem cell recipients with multiple myeloma identifies 11 genetic variants associated with chemotherapy-induced oral mucositis. Support Care Cancer. 2015 Mar; 23(3):841-9.
-
Bhatt VR, Akhtari M, Bociek RG, Sanmann JN, Yuan J, Dave BJ, Sanger WG, Kessinger A, Armitage JO. Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute myeloid leukemia. J Natl Compr Canc Netw. 2014 Jul; 12(7):963-8.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|